Healthcare Dec 02, 2021 09:42 AM (GMT+8) · EqualOcean
Recently, Xiansheng pharmaceutical announced that the application for listing license of tralaciclib for injection, a bone marrow protection innovative drug, submitted to the State Drug Administration has been accepted. Traracillin, developed by Xiansheng pharmaceutical in cooperation with G1 therapeutics, is the world's first and only drug with comprehensive bone marrow protection effect. It can reduce bone marrow suppression (CIM) caused by chemotherapy. It has been listed in the United States in February this year (trade name: cosela) ™)。 The first indication applied in China is preventive use in patients with extensive stage small cell lung cancer receiving platinum containing drugs combined with etoposide regimen to reduce the incidence of chemotherapy-induced bone marrow suppression.